<DOC>
	<DOCNO>NCT01740960</DOCNO>
	<brief_summary>The result phase I Namisol® study ( Klumpers et al . Br J Clin Pharmacol , 2012 ) , implicate Namisol® may favorable PK PD characteristic safe use people . However , study include young adult mean age 21.4 year . In previous THC study , subject age associate treatment response tolerance adverse reaction . This association support Lane et al . Volicer et al . There concern safety tolerability THC elderly population . This , elderly person general high risk adverse drug reaction due combination physiological factor decrease lean body mass , reduction renal hepatic clearance , medical comorbidity lead polypharmacy drug-drug interaction . Therefore , data phase I trial translate directly elderly ( likely vulnerable ) population . This make important evaluate safety tolerability profile different Namisol® dose elderly . In study progress `` Delta-THC Behavioral Disturbances Dementia '' , Namisol® dose 0,75 mg 1,5 mg , , well tolerate elderly subject . These dos , however , low comparison dos use phase I study young adult ( 5 mg , 6,5 mg 8 mg ) . The current study safety tolerability relatively high dos Namisol® help u future provide broad advice therapeutic index safety profile Namisol® elderly population .</brief_summary>
	<brief_title>Safety Tolerability Namisol Elderly</brief_title>
	<detailed_description>Subjects visit site 5 time . The first visit , 2 hour screen visit eligibility volunteer sign informed consent medical history , physical examination , ECG , hematological biochemical blood test , Mini Mental State Examination ( MMSE ) , Geriatric Depression scale ( GDS-30 ) body sway test . Eligible subject randomly allocate receive three dos Namisol® ( 3 mg 5 mg 6,5 mg ) placebo double-blind crossover design ( visit 1 4 ) . The wash-out period visit least 2 week maximum 4 week . Each visit precede baseline assessment measure . The safety tolerability profile Namisol® evaluate intervention visit use standardized THC adverse effect checklist self-reporting , vital sign , 12-lead ECG , body sway , Visual Analogue Scales ( subtest feel high ) , Test Attentional Performance ( TAP , subtest alertness ) follow phone call follow day . Four blood sample collect visit determine relationship pharmacodynamic effect ( VAS-feeling high , TAP-alertness body sway ) plasma concentration THC active metabolite 11‐OH‐THC THC-COOH . In addition , blood sample collect first intervention day genotyping cytochrome P450 enzymes CYP2C9 CYP2C19 CYP3A4 .</detailed_description>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Subject healthy old person establish medical history , physical examination , electrocardiography , result hematological biochemical blood test screen . Age 65 year Body mass index 18.0 30 kg m2 Subject able willing sign Informed Consent Form prior screen evaluation Regular cannabis user , define : smoke one joint per week Documented history sensitivity/idiosyncrasy cannabis Relevant history presence severe pulmonary disorder [ e.g . COPD GOLD III IV ] , serious cardiovascular disorder [ e.g . myocardial infarction &lt; 6 month ago ; atrial fibrillation ; heart failure NYHA III IV ; severe heart valve disease , orthostatic hypotension define systolic drop 20 mm Hg Safety Tolerability Namisol Elderly Page 8 Version 2 , 10 07 2012 diastolic drop 10 mm Hg ] , seizures , migraine , psychiatric disorder [ e.g . depression ( base document history GDS30 screen ≥ 10 ) ; mania ; psychosis ; dementia ] , cognitive impairment [ base documented history MMSE screen &lt; 28 , significant renal ( GFR &lt; 30 ml/min ) hepatic disorder [ e.g . cancer , cirrhosis . ALT AST ≥ twice upper limit normal ] , diabetes mellitus , coagulation disorder Inability understand nature extent trial procedure require Current alcohol abuse use 2 alcoholic consumption daily History , current drug abuse Using drug inhibitor CYP2C9 , CYP2C19 CYP3A4 ( see appendix 13.3 ) Participation drug trial within 60 day prior first intervention day Donation blood within 60 day prior first intervention day Known lactose intolerance Using six unit ( methyl ) xanthine product per day ( e.g . coffee , tea , cola , chocolate ) Smoking ten cigarette per day High fallrisk ( base body sway test )</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>delta-9-tetrahydrocannabinol</keyword>
	<keyword>THC</keyword>
	<keyword>Cannabis</keyword>
</DOC>